Rigel Pharmaceuticals (RIGL) Operating Leases (2019 - 2026)

Rigel Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $228000.0 for Q1 2026.

• In Q1 2026, Operating Leases fell 73.61% year-over-year to $228000.0; the TTM figure through Mar 2026 stood at $228000.0 (down 73.61% YoY), while the FY2025 annual figure was $395000.0, changed N/A from the prior year.
• Operating Leases was $228000.0 for Q1 2026 at Rigel Pharmaceuticals, down from $395000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $8.3 million in Q1 2022 to a low of $100000.0 in Q1 2024.
• Historically, Operating Leases has averaged $1.2 million across 5 years, with a median of $592000.0 in 2023.
• The sharpest annual moves came in 2023 and 2025: Operating Leases tumbled 90.34% in 2023, then jumped 764.0% in 2025.
• A 5-year view of Operating Leases shows it stood at $972000.0 in 2022, then tumbled by 70.68% to $285000.0 in 2023, then sank by 64.91% to $100000.0 in 2024, then surged by 295.0% to $395000.0 in 2025, then tumbled by 42.28% to $228000.0 in 2026.
• The last three Operating Leases figures came in at $228000.0 (Q1 2026), $395000.0 (Q4 2025), and $556000.0 (Q3 2025), per Business Quant data.